Caribou Biosciences Inc (CRBU)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.570.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CRBU
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 6.2% |
| Our one-year growth estimate | diamond | 30.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 24.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CRBU — litigation filed
Dated 2026-06-11
Other Events. On June 11, 2026 , the Company announced long-term follow-up data from its ANTLER phase 1 clinical trial that evaluated vispa-cel, an off-the-shelf CD19-targeted CAR-T cell therapy product candidate, in patients with r/r B-NHL. The Company also announced longer follow-up data from the dose escalation portion of its ongoing CaMMouflage phase 1 clinical trial evaluating CB-011, an off-the-shelf BCMA-targeted CAR-T cell therapy product candidate, in patients with r/r MM. The Compan…
Why it matters: Enrollment progress shows interest in vispa-cel for the main trial. This is key for future funding.
Supportive ifAbout 250 patients are enrolled in the ANTLER-3 trial. This is on track.
Worry ifEnrollment is delayed or fewer than 100 patients are enrolled by the end of the year.
Why it matters: Good news on CB-011 could boost its status as a top therapy for multiple myeloma. This helps the company's growth.
Supportive ifUpdates show overall response rate for CB-011 remains above 90% in ongoing trials.
Worry ifResponse rates fall under 70%. Safety issues are reported.
Why it matters: Getting funding is key to carrying out the plan into the second half of 2027.
Supportive ifThey announced new funding or partnerships to help support the plan.
Worry ifThey fail to get funding or face delays in getting money.
Why it matters: Updates on CB-011's dose expansion could show it is a top therapy for multiple myeloma.
Supportive ifManagement shares initial data showing a 92% overall response rate. The complete response rate is 75%.
Worry ifData shows overall response rate below 70% or complete response rate below 50%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$212 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $688 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,106 loss on $10,000 · 51.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The results of the lawsuits could change how Caribou operates and its finances.
Worry ifThe lawsuit ends in Caribou's favor, leading to a better outlook.
Less concerning ifThere are bad news or rulings in the ongoing lawsuits.
Why it matters: Data from the ANTLER trial could change how investors feel. It may affect the company's future.
Watch forGood long-term follow-up data from the ANTLER trial is released.
Also watch forNegative findings or lack of updates from the ANTLER trial.
Why it matters: Funding is crucial for the ANTLER-3 trial. Without it, the trial's progress may be delayed.
Watch forAnnouncement of a new funding round or partnership that secures at least $50 million for the ANTLER-3 trial.
Also watch forThere are no funding announcements. There are also no delays in trial preparations due to funding.
Why it matters: Updates from the FDA will clarify the path forward for vispa-cel in treating large B cell lymphoma. This could impact funding and investor confidence.
Supportive ifThe FDA gave positive feedback on the ANTLER-3 trial design. It meets regulatory rules.
Worry ifFDA raises concerns about the ANTLER-3 trial design, delaying the trial start.
Why it matters: This data could show if vispa-cel works for 2L LBCL patients. Good results would help it become a top therapy.
Supportive ifPresentation at the EHA on June 12, 2026, shows overall response rate above 80%.
Worry ifData shows the overall response rate is below 80%. This raises safety concerns.
Why it matters: Initial data will show how well vispa-cel performs compared to standard treatments. This is key for its future.
Supportive ifThe first results from the ANTLER-3 trial show better progression-free survival than standard care.
Worry ifThe first data shows vispa-cel does not improve progression-free survival. This is compared to standard care.
Why it matters: Updates will reveal how effective CB-011 is for patients with multiple myeloma. This impacts its market potential.
Supportive ifThe first dose expansion data from the CaMMouflage trial shows a response rate over 90%.
Worry ifData shows a low overall response rate below 70% for CB-011 in the dose expansion cohort.
Why it matters: Funding is critical for the ANTLER-3 trial. Announcements will indicate if the company can proceed as planned.
Watch forCaribou announces a deal that secures at least $50 million for the ANTLER-3 trial.
Also watch forNo funding news is shared, raising worries about paying for the ANTLER-3 trial.